A test strip for detecting Aβ in urine includes a polyvinyl chloride (PVC) bottom plate. The PVC bottom plate is laid with a sample pad, a conjugation pad, a chromatography pad, and an absorbent pad that are overlapped in sequence. The conjugation pad is coated with colloidal gold particles conjugated to a monoclonal antibody. The chromatography pad is provided with a test line on the side proximate to the conjugation pad, and is provided with a control line on the side proximate to the absorbent pad. The test line is coated with an Aβ-binding polymer. The control line is coated with a goat anti-mouse IgG polyclonal antibody. The method is suitable for the following: routine clinical pathological examination; general screening of a large number of people and self-screening of home end-users; assisting the early diagnosis and prejudgment of mild cognitive impairment (MCI) clinically.

A microfluidic device for detection of an analyte in a fluid is described. The microfluidic device comprises a substrate having a first surface defining entrances to one or more chambers defined in the substrate, surfaces of the chambers defining a second surface of the substrate, the first surface being modified for selective targeting and capture of at least one analyte to operably effect a blocking of the entrance to at least one of the chambers, and wherein a response characteristic of the microfluidic device is operably varied by the blocking of the entrance to the at least one of the chambers, thereby providing an indication of the presence of the analyte within the fluid.

A microfluidic device for detection of an analyte in a fluid is described. The microfluidic device comprises a substrate having a first surface defining entrances to one or more chambers defined in the substrate, surfaces of the chambers defining a second surface of the substrate, the first surface being modified for selective targeting and capture of at least one analyte to operably effect a blocking of the entrance to at least one of the chambers, and wherein a response characteristic of the microfluidic device is operably varied by the blocking of the entrance to the at least one of the chambers, thereby providing an indication of the presence of the analyte within the fluid.

The invention provides anti-Tau antibodies and methods of using the same.

The invention provides anti-Tau antibodies and methods of using the same.

A reagent for extracting immunosuppressant drugs from a whole blood sample for immunoassay includes protein denaturant, proteolytic enzyme, surfactant and pH buffer. A method and an immunoassay kit for detection of the immunosuppressant concentration in a whole blood sample uses the extraction reagent. The extraction reagent doesn't need the use of organic solvent as that in the traditional extraction methods, therefore the adverse effects of the organic solvent on the antibody activity in a detection system and the other relative defects associated to its use are obviated. The drug extraction process doesn't need centrifugation, as the processed sample can be directly applied for immunoassay. The operation for drug extraction is simple, and the detection result based on this extraction method is accurate.

A reagent for extracting immunosuppressant drugs from a whole blood sample for immunoassay includes protein denaturant, proteolytic enzyme, surfactant and pH buffer. A method and an immunoassay kit for detection of the immunosuppressant concentration in a whole blood sample uses the extraction reagent. The extraction reagent doesn't need the use of organic solvent as that in the traditional extraction methods, therefore the adverse effects of the organic solvent on the antibody activity in a detection system and the other relative defects associated to its use are obviated. The drug extraction process doesn't need centrifugation, as the processed sample can be directly applied for immunoassay. The operation for drug extraction is simple, and the detection result based on this extraction method is accurate.

Provided is a novel high sensitive method for assaying misfolded SOD1 in a body fluid of a subject, in particular in the cerebrospinal fluid. This method is based on a novel highly sensitive immunoassay making use of a unique epitope of SOD1 and corresponding anti-SOD1 antibodies. In addition, kits comprising the components of the immunoassay are provided.

The invention provides an assay method for an assay system using an anti-immunocomplex antibody, which is able to increase reaction efficiency. The n immunoassay method uses: an anti-hapten rabbit monoclonal antibody immobilized on a water-insoluble carrier, and a labeled anti-immunocomplex antibody,
wherein the method comprises the following steps (i) to (iii): (i) a step of reacting the anti-hapten rabbit monoclonal antibody immobilized on the water-insoluble carrier with a hapten in a solution to be measured, (ii) a step of reacting the labeled anti-immunocomplex antibody with the hapten-anti-hapten rabbit monoclonal antibody immune complex, and (iii) a step of detecting the signal from the label.

The invention provides an assay method for an assay system using an anti-immunocomplex antibody, which is able to increase reaction efficiency. The n immunoassay method uses: an anti-hapten rabbit monoclonal antibody immobilized on a water-insoluble carrier, and a labeled anti-immunocomplex antibody,
wherein the method comprises the following steps (i) to (iii): (i) a step of reacting the anti-hapten rabbit monoclonal antibody immobilized on the water-insoluble carrier with a hapten in a solution to be measured, (ii) a step of reacting the labeled anti-immunocomplex antibody with the hapten-anti-hapten rabbit monoclonal antibody immune complex, and (iii) a step of detecting the signal from the label.